Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 14/20 | 1.00 |
| ▸ | SUCNR1 | Q9BXA5 | 7/20 | 1.00 |
| ▸ | F11 | P03951 | 2/20 | 1.00 |
| ▸ | TPSB2 | P20231 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16397460 | 0.91 | CFD (0.83) | CFDSUCNR1F11TPSB2 | |
| SCHEMBL16396970 | 0.90 | CFD (0.82) | CFDSUCNR1F11TPSB2 | |
| SCHEMBL16396967 | 0.90 | CFD (0.82) | CFDSUCNR1F11TPSB2 | |
| SCHEMBL26263428 | 0.89 | CFD (0.81) | CFDSUCNR1F11TPSB2 | |
| SCHEMBL17802739 | 0.89 | SUCNR1 (0.81) | CFDSUCNR1F11TPSB2 | |
| SCHEMBL16396686 | 0.89 | CFD (0.80) | CFDSUCNR1F11TPSB2 | |
| SCHEMBL16397325 | 0.89 | CFD (0.80) | CFDSUCNR1F11TPSB2 | |
| SCHEMBL16410319 | 0.89 | SUCNR1 (0.80) | CFDSUCNR1F11TPSB2 | |
| SCHEMBL16396465 | 0.87 | CFD (1.00) | CFDSUCNR1F11TPSB2 | |
| SCHEMBL16397100 | 0.86 | CFD (0.76) | CFDSUCNR1F11TPSB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183776-A2 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | UNIV NEW YORK (US) | 2023-09-21 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | NOVARTIS AG (CH) | 2016-05-26 | — | — | US | disclosed |
| EP-3022182-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
| WO-2015009977-A1 | AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF | NOVARTIS AG (CH) | 2015-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293504-A1 | TARGETING SUCNR1 TO REDUCE NEUROINFLAMMATION | SUCNR1, SYNGR2, TSPO | CFD 4870/4885SUCNR1 1/4885F11 4510/4885 |
| US-20160145247-A1 | Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof | CFD, CFH, CFB | CFD 1/4885SUCNR1 4670/4885F11 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.